RENB Renovaro Biosciences Inc
Price (delayed)
$0.5735
Market cap
$84.59M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.1
Enterprise value
$92.85M
enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and
Highlights
The equity has surged by 103% year-on-year
Renovaro Biosciences's net income has plunged by 114% from the previous quarter but it has increased by 17% YoY
The company's EPS has shrunk by 57% QoQ but it rose by 46% YoY
Renovaro Biosciences's quick ratio has shrunk by 96% YoY and by 90% QoQ
The debt has increased by 22% year-on-year and by 16% since the previous quarter
Key stats
What are the main financial stats of RENB
Market
Valuations
Earnings
Shares outstanding
147.5M
Market cap
$84.59M
Enterprise value
$92.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.61
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$87.21M
EBITDA
-$87.09M
Free cash flow
-$10.87M
Per share
Balance sheet
Liquidity
EPS
-$1.1
Free cash flow per share
-$0.1
Book value per share
$0.94
Revenue per share
$0
TBVPS
$0.03
Total assets
$178.09M
Total liabilities
$43.68M
Debt
$8.57M
Equity
$134.41M
Working capital
-$19.65M
Debt to equity
0.06
Current ratio
0.06
Quick ratio
0.01
Net debt/EBITDA
-0.09
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-100.1%
Return on equity
-129.9%
Return on invested capital
N/A
Return on capital employed
-55.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RENB stock price
How has the Renovaro Biosciences stock price performed over time
Intraday
-5.21%
1 week
-12.09%
1 month
-15.45%
1 year
-80.16%
YTD
-81.91%
QTD
-67.23%
Financial performance
How have Renovaro Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$87.47M
Net income
-$88.12M
Gross margin
N/A
Net margin
N/A
RENB's operating income has shrunk by 118% QoQ but it is up by 23% YoY
Renovaro Biosciences's net income has plunged by 114% from the previous quarter but it has increased by 17% YoY
Growth
What is Renovaro Biosciences's growth rate over time
Valuation
What is Renovaro Biosciences stock price valuation
P/E
N/A
P/B
0.61
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has shrunk by 57% QoQ but it rose by 46% YoY
The equity has surged by 103% year-on-year
The stock's P/B is 81% below its last 4 quarters average of 3.5 and 64% below its 5-year quarterly average of 1.8
Efficiency
How efficient is Renovaro Biosciences business performance
RENB's ROE has dropped by 60% since the previous quarter but it is up by 16% year-on-year
The ROA has plunged by 53% from the previous quarter but it has grown by 23% YoY
Dividends
What is RENB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RENB.
Financial health
How did Renovaro Biosciences financials performed over time
RENB's total assets has soared by 126% YoY
Renovaro Biosciences's quick ratio has shrunk by 96% YoY and by 90% QoQ
The debt is 94% smaller than the equity
The equity has surged by 103% year-on-year
The debt to equity has dropped by 65% since the previous quarter and by 45% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.